

John R Mascola

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4930036/john-r-mascola-publications-by-citations.pdf>

Version: 2022-11-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

389
papers

50,647
citations

118
h-index

216
g-index

411
ext. papers

60,845
ext. citations

18
avg. IF

7.54
L-index

#	Paper	IF	Citations
389	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021 , 384, 403-416	57.3	3482
388	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. <i>New England Journal of Medicine</i> , 2020 , 383, 1920-1931	57.3	1650
387	Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. <i>Science</i> , 2010 , 329, 856-61	32.2	1336
386	Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. <i>Nature Medicine</i> , 2000 , 6, 207-10	49.4	1143
385	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021 , 593, 130-135	47.5	955
384	Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. <i>Journal of Virology</i> , 2005 , 79, 10108-25	6.3	936
383	Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. <i>Science</i> , 2010 , 329, 811-7	32.2	874
382	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013 , 496, 469-76	47.5	755
381	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. <i>Nature</i> , 2009 , 458, 636-40	47.5	706
380	Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. <i>Science</i> , 2011 , 333, 1593-602	32.2	690
379	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011 , 480, 336-43	47.5	675
378	Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. <i>Journal of Virology</i> , 1999 , 73, 4009-18	6.3	651
377	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , 2012 , 491, 406-12	47.5	617
376	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020 , 383, 1544-1555	57.3	593
375	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014 , 514, 455-61	47.5	568
374	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020 , 586, 567-571	47.5	559
373	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014 , 509, 55-62	47.5	534

372	Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. <i>Journal of Virology</i> , 2010 , 84, 1439-52	6.3	511
371	Human skin Langerhans cells are targets of dengue virus infection. <i>Nature Medicine</i> , 2000 , 6, 816-20	49.4	509
370	Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. <i>New England Journal of Medicine</i> , 2013 , 369, 2083-923	97.3	436
369	The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. <i>Nature Medicine</i> , 1997 , 3, 338-40	49.4	431
368	Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. <i>Journal of Virology</i> , 2004 , 78, 10724-37	6.3	419
367	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015 , 21, 1065-70	49.4	408
366	Gene transfer in humans using a conditionally replicating lentiviral vector. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 17372-7	11.2	395
365	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021 , 384, 80-82	57.3	389
364	Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. <i>Immunity</i> , 2012 , 37, 412-25	31.5	365
363	HIV-1 neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013 , 254, 225-44	44	367
362	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009 , 15, 866-70	49.4	357
361	Broad HIV-1 neutralization mediated by CD4-binding site antibodies. <i>Nature Medicine</i> , 2007 , 13, 1032-4	49.4	346
360	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.3	334
359	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. <i>Nature</i> , 2014 , 515, 138-42	47.5	327
358	The role of antibodies in HIV vaccines. <i>Annual Review of Immunology</i> , 2010 , 28, 413-44	33.6	322
357	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. <i>Immunity</i> , 2013 , 38, 176-86	31.5	322
356	Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. <i>Science</i> , 2006 , 312, 1530-3	32.2	316
355	Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. <i>Journal of Virology</i> , 2008 , 82, 11651-68	6.3	306

354	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015 , 7, 319ra206	16.9	307
353	Antibody responses to envelope glycoproteins in HIV-1 infection. <i>Nature Immunology</i> , 2015 , 16, 571-6	18.5	303
352	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016 , 165, 813-26	54.6	295
351	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. <i>Journal of Immunological Methods</i> , 2014 , 409, 131-46	2.4	287
350	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016 , 354, 237-240	32.2	282
349	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 2259-2261	57.3	283
348	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016 , 351, 1339-42	32.2	280
347	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016 , 375, 2037-2050	57.3	280
346	A strategic approach to COVID-19 vaccine R&D. <i>Science</i> , 2020 , 368, 948-950	32.2	272
345	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1117-34	16.1	257
344	Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. <i>Journal of Virology</i> , 2010 , 84, 1631-6	6.3	257
343	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. <i>Nature Reviews Immunology</i> , 2013 , 13, 693-701	35.6	258
342	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. <i>Immunity</i> , 2013 , 39, 245-58	31.5	253
341	Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. <i>Journal of Virology</i> , 2009 , 83, 188-99	6.3	258
340	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <i>Nature Structural and Molecular Biology</i> , 2015 , 22, 522-31	17.1	250
339	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. <i>Aids</i> , 2014 , 28, 163-9	3.4	251
338	Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. <i>Science</i> , 2009 , 326, 1123-7	32.2	249
337	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. <i>Nature Medicine</i> , 2014 , 20, 1126-9	49.4	256

336	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014 , 211, 2061-74	16.1	242
335	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016 , 533, 105-109	47.5	233
334	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014 , 514, 642-5	47.5	228
333	Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. <i>Journal of Virology</i> , 2009 , 83, 1045-59	6.3	225
332	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. <i>Immunity</i> , 2016 , 45, 1108-1121	31.5	219
331	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015 , 161, 1280-92	54.6	217
330	Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013 , 20, 804-13	17.1	219
329	Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. <i>Journal of Virology</i> , 2005 , 79, 10103-7	6.3	217
328	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015 , 6, 7712	16.9	214
327	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016 , 352, 828-33	32.2	214
326	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. <i>Cell</i> , 2014 , 158, 481-94	34.6	211
325	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016 , 166, 609-623	54.6	209
324	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016 , 165, 449-63	54.6	206
323	The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. <i>Nature</i> , 2003 , 426, 853-7	7.5	201
322	Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. <i>Journal of Virology</i> , 2014 , 88, 2489-507	6.3	199
321	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5663-8	11.2	199
320	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. <i>Journal of Virology</i> , 2014 , 88, 12669-82	6.3	195
319	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014 , 6, 243ra88	16.9	188

3 ¹⁸	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <i>PLoS ONE</i> , 2013 , 8, e75665	3.6	187
3 ¹⁷	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008 , 26, 6338-43	4	191
3 ¹⁶	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. <i>Nature Medicine</i> , 2016 , 22, 1456-1464	49.4	187
3 ¹⁵	Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. <i>Journal of Virology</i> , 2010 , 84, 8098-110	6.3	184
3 ¹⁴	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015 , 162, 1090-100	54.6	176
3 ¹³	Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. <i>Journal of Virology</i> , 2011 , 85, 8954-67	6.3	177
3 ¹²	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <i>Cell</i> , 2015 , 161, 470-485	54.6	175
3 ¹¹	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. <i>Immunity</i> , 2018 , 48, 855-871	31.5	177
3 ¹⁰	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017 , 376, 928-938	57.3	183
3 ⁰⁹	Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. <i>Journal of Virology</i> , 2005 , 79, 8861-9	6.3	173
3 ⁰⁸	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017 , 358, 85-90	32.2	175
3 ⁰⁷	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018 , 391, 552-562	36.3	173
3 ⁰⁶	Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. <i>Science</i> , 2013 , 340, 751-6	32.2	170
3 ⁰⁵	A method for identification of HIV gp140 binding memory B cells in human blood. <i>Journal of Immunological Methods</i> , 2009 , 343, 65-7	2.4	170
3 ⁰⁴	Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2005 , 201, 2023-33	16.1	167
3 ⁰³	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018 , 24, 857-867	49.4	166
3 ⁰²	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2014 , 384, 2046-52	36.3	166
3 ⁰¹	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. <i>Science Translational Medicine</i> , 2011 , 3, 81ra36	16.9	164

300	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	16.9	160
299	The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1444-57.	1.5	157
298	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases</i> , 2011 , 11, 916-24	24.7	159
297	Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. <i>Cell Reports</i> , 2016 , 16, 1485-1491	10.3	157
296	Monoclonal Antibodies for Prevention and Treatment of COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 131-132	26.8	158
295	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015 , 21, 1332-6	49.4	151
294	A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1732-40	6.9	152
293	Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. <i>Journal of Infectious Diseases</i> , 1994 , 169, 48-54	6.9	150
292	Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. <i>Journal of Virology</i> , 2009 , 83, 8925-37	6.3	151
291	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. <i>Journal of Virology</i> , 2011 , 85, 11502-19	6.3	148
290	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016 , 90, 76-91	6.3	148
289	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015 , 349, aab1253	32.2	143
288	Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. <i>Journal of Virology</i> , 1998 , 72, 6040-7	6.3	140
287	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021 , 373, 1372-1377	32.2	137
286	Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. <i>Journal of Virology</i> , 2012 , 86, 4688-92	6.3	134
285	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , 2016 , 22, 362-8	49.4	134
284	Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDS VAX HIV-1 vaccine efficacy trial. <i>PLoS ONE</i> , 2013 , 8, e53629	3.6	131
283	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016 , 166, 1471-1484.e18	54.6	128

282	A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. <i>Journal of Virology</i> , 2005 , 79, 8828-34	6.3	129
281	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 81-90	17.1	127
280	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. <i>Vaccine</i> , 2007 , 25, 4085-92	4	126
279	Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. <i>Journal of Virology</i> , 2005 , 79, 6516-22	6.3	128
278	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	16.9	122
277	Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. <i>Journal of Virology</i> , 2004 , 78, 7490-7	6.3	122
276	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017 , 19, 719-732	10.3	121
275	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018 , 92,	6.3	119
274	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014 , 505, 502-8	47.5	122
273	Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6470-5	11.2	119
272	Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. <i>PLoS ONE</i> , 2010 , 5, e9015	3.6	119
271	Human dendritic cells as targets of dengue virus infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001 , 6, 219-24	1.1	116
270	Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011 , 1, a007278	5.2	114
269	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. <i>PLoS Medicine</i> , 2018 , 15, e1002493	11.3	116
268	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015 , 11, e1004932	7.4	113
267	A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1396-404	6.8	114
266	Defining the protective antibody response for HIV-1. <i>Current Molecular Medicine</i> , 2003 , 3, 209-16	2.4	117
265	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019 , 365, 505-509	5.9	113

264	Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. <i>Journal of Virology</i> , 2005 , 79, 2956-63	6.3	111
263	Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. <i>Journal of Virology</i> , 2005 , 79, 8878-85	6.3	110
262	The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. <i>Journal of Virology</i> , 2004 , 78, 2394-404	6.3	109
261	Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. <i>Journal of Clinical Microbiology</i> , 1999 , 37, 2557-63	9.5	109
260	Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. <i>PLoS Pathogens</i> , 2009 , 5, e1000445	7.4	107
259	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	16.9	104
258	Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. <i>Journal of Virology</i> , 2000 , 74, 11329-38	6.3	104
257	The development of CD4 binding site antibodies during HIV-1 infection. <i>Journal of Virology</i> , 2012 , 86, 7588-95	6.3	103
256	Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. <i>Journal of Virology</i> , 2002 , 76, 4810-21	6.3	102
255	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005520	7.4	103
254	Use of broadly neutralizing antibodies for HIV-1 prevention. <i>Immunological Reviews</i> , 2017 , 275, 296-312	11	102
253	Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. <i>Journal of Virology</i> , 2015 , 89, 2659-71	6.3	99
252	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. <i>Cell Host and Microbe</i> , 2014 , 16, 304-13	22.9	99
251	PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. <i>Journal of Virology</i> , 2012 , 86, 4394-403	6.3	97
250	Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. <i>Journal of Virology</i> , 2010 , 84, 2955-62	6.3	96
249	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019 , 20, 362-372	18.5	94
248	Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. <i>Journal of Virology</i> , 2005 , 79, 771-9	6.3	95
247	Isolation of human monoclonal antibodies from peripheral blood B cells. <i>Nature Protocols</i> , 2013 , 8, 1907-18	18.1	93

246	Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. <i>Journal of Virology</i> , 2007 , 81, 5579-93	6.3	94
245	HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. <i>Journal of Virology</i> , 2015 , 89, 4201-13	6.3	90
244	Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. <i>Science Translational Medicine</i> , 2015 , 7, 298ra120	16.9	88
243	Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. <i>Journal of Experimental Medicine</i> , 2010 , 207, 2003-17	16.1	88
242	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. <i>Virology</i> , 2006 , 350, 34-47	3.5	89
241	Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. <i>Aids</i> , 2000 , 14, 1009-15	3.4	90
240	High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. <i>Science Translational Medicine</i> , 2012 , 4, 142ra96	16.9	86
239	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. <i>Journal of Virology</i> , 2015 , 89, 5318-29	6.3	85
238	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet, The</i> , 2015 , 385, 1545-54	36.3	85
237	Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. <i>Journal of Virology</i> , 2012 , 86, 8672-80	6.3	87
236	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017 , 2,	27.4	84
235	Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. <i>Journal of Virology</i> , 2009 , 83, 10892-907	6.3	84
234	Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. <i>Journal of Virology</i> , 2009 , 83, 11265-74	6.3	84
233	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 5895-903	6.3	82
232	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017 , 9,	16.9	82
231	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021 , 184, 4203-4219.e32	54.6	81
230	De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4088-97	11.2	80
229	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021 , 373, eabj0299	32.2	80

228	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 8334-45	6.3	79
227	Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 4382-96	8	78
226	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021 , 385, 1774-1785	57.3	84
225	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 811-820	17.1	76
224	Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. <i>Journal of Virology</i> , 2011 , 85, 11401-8	6.3	75
223	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 239-252	62.2	77
222	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021 , 373,	32.2	75
221	Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. <i>Journal of Virology</i> , 1998 , 72, 9788-94	6.3	75
220	Functional interrogation and mining of natively paired human V:V antibody repertoires. <i>Nature Biotechnology</i> , 2018 , 36, 152-155	43.2	73
219	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017 , 13, 1115-1122	11.3	72
218	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017 , 14, e1002435	11.3	74
217	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet, The</i> , 2019 , 393, 889-898	36.3	72
216	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , 2015 , 6, 8447	16.9	72
215	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1835-43	15.4	72
214	Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. <i>Journal of Immunology</i> , 2014 , 192, 1100-1106	5.2	71
213	The quest for an antibody-based HIV vaccine. <i>Immunological Reviews</i> , 2017 , 275, 5-10	11	70
212	Multiple roles for HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2019 , 11,	16.9	69
211	A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. <i>Journal of Virology</i> , 2012 , 86, 8319-23	6.3	69

210	Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. <i>Journal of Virology</i> , 2012 , 86, 5844-56	6.3	68
209	Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 1319-28	1.5	68
208	Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. <i>Journal of Virology</i> , 2004 , 78, 4029-36	6.3	68
207	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017 , 21, 3681-3690	10.3	65
206	Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. <i>Journal of Virology</i> , 2011 , 85, 6906-12	6.3	65
205	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019 , 178, 567-584.e19	54.6	62
204	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017 , 9,	16.9	63
203	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021 , 384, 1003-1014	57.3	67
202	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. <i>Immunity</i> , 2016 , 44, 939-50	31.5	61
201	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017 , 91,	6.3	61
200	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. <i>Immunity</i> , 2017 , 46, 804-817.e7	31.5	61
199	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness 2020 ,		61
198	HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. <i>Journal of Virology</i> , 2012 , 86, 3393-7	6.3	60
197	Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. <i>Nature Communications</i> , 2015 , 6, 6565	16.9	59
196	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. <i>Immunity</i> , 2019 , 51, 915-929.e7	31.5	58
195	Vaccines for the prevention of HIV-1 disease. <i>Current Opinion in Immunology</i> , 2001 , 13, 489-95	7.5	58
194	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016 , 90, 1321-32	6.3	57
193	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017 , 9,	16.9	57

192	B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. <i>PLoS Pathogens</i> , 2008 , 4, e1000171	7.4	57
191	Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. <i>Aids</i> , 2003 , 17, 2521-7	3.4	57
190	Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. <i>Frontiers in Immunology</i> , 2017 , 8, 537	8.2	56
189	Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. <i>Journal of Virology</i> , 2014 , 88, 12623-43	6.3	56
188	Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1431-1432	26.8	56
187	DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. <i>PLoS ONE</i> , 2013 , 8, e59340	3.6	57
186	Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. <i>Journal of Virology</i> , 2013 , 87, 10047-58	6.3	54
185	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015 , 18, 354-62	22.9	53
184	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019 , 25, 59-72.e8	22.9	53
183	Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics. <i>Frontiers in Microbiology</i> , 2012 , 3, 315	5.5	53
182	Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. <i>Journal of Virology</i> , 2013 , 87, 13239-51	6.3	53
181	Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19769-74	11.2	55
180	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4838-4849	15.4	53
179	Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. <i>Journal of Virology</i> , 2009 , 83, 540-51	6.3	52
178	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017 , 8, 1732	16.9	51
177	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019 , 50, 1513-1529.e9	31.5	50
176	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017 , 9,	0.8	50
175	HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. <i>Journal of Virology</i> , 2012 , 86, 11231-41	6.3	50

174	No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. <i>Journal of Virology</i> , 2007 , 81, 12368-74	6.3	50
173	Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. <i>ACS Medicinal Chemistry Letters</i> , 2013 , 4, 338-343	4.1	49
172	Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. <i>Journal of Biological Chemistry</i> , 2012 , 287, 5673-86	5.1	49
171	Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. <i>Journal of Virology</i> , 2006 , 80, 10950-6	6.3	50
170	Anti-HIV B Cell lines as candidate vaccine biosensors. <i>Journal of Immunology</i> , 2012 , 189, 4816-24	5.2	49
169	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018 , 4, 788-796	5.4	47
168	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019 , 27, 196-206.e6	5	47
167	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. <i>MBio</i> , 2019 , 10,	7.6	45
166	Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. <i>Journal of Immunology</i> , 2014 , 192, 3637-44	5.2	46
165	Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. <i>Journal of Virology</i> , 2003 , 77, 10348-56	6.3	46
164	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2015 , 90, 2740-55	6.3	45
163	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019 , 6, e297-e306	7.5	47
162	HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 877-87	1.5	45
161	Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. <i>Journal of Virology</i> , 2002 , 76, 11484-90	6.3	45
160	Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. <i>Journal of Virology</i> , 1999 , 73, 4640-50	6.3	45
159	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016 , 90, 5899-5914	6.3	44
158	Novel vaccine technologies for the 21st century. <i>Nature Reviews Immunology</i> , 2020 , 20, 87-88	35.6	44
157	Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. 2021 ,		45

156	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018 , 14, e1006860	7.4	43
155	Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. <i>Journal of Virology</i> , 2011 , 85, 5465-75	6.3	42
154	Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. <i>Journal of Virology</i> , 2009 , 83, 5077-86	6.3	42
153	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , 2018 , 9, 877	16.9	41
152	Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. <i>Journal of Virology</i> , 2011 , 85, 4578-85	6.3	41
151	Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. <i>Journal of Virology</i> , 2012 , 86, 8516-26	6.3	41
150	Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. <i>Journal of Virology</i> , 2010 , 84, 1683-95	6.3	41
149	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 12265-12270	11.2	40
148	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019 , 26, 336-346.e3	22.9	39
147	SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. <i>Frontiers in Immunology</i> , 2016 , 7, 372	8.2	39
146	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016 , 12, e1005537	7.4	39
145	Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. <i>Journal of Virology</i> , 2011 , 85, 2524-35	6.3	39
144	The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. <i>Journal of Virology</i> , 2011 , 85, 10389-98	6.3	40
143	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.. <i>New England Journal of Medicine</i> , 2022 ,	57.3	40
142	Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. <i>Journal of Virology</i> , 2008 , 82, 6869-79	6.3	38
141	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019 , 50, 677-691.e13	31.5	37
140	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017 , 13, e1006148	7.4	36
139	The changing face of HIV vaccine research. <i>Journal of the International AIDS Society</i> , 2012 , 15, 17407	5.3	36

138	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , 2021 , 592, 623-628	47.5	37
137	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2372-2385	6.1	35
136	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020 , 33, 108322	10.3	35
135	Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. <i>Journal of Virology</i> , 2005 , 79, 10902-14	6.3	35
134	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016 , 11, e0157409	3.6	34
133	Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. <i>Journal of Virology</i> , 2007 , 81, 13486-98	6.3	34
132	Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. <i>Journal of Virology</i> , 2004 , 78, 5270-8	6.3	34
131	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018 , 22, 1798-1809	10.3	33
130	Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. <i>Journal of Virology</i> , 2014 , 88, 2426-41	6.3	33
129	Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. <i>Journal of Virology</i> , 1998 , 72, 9656-67	6.3	33
128	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017 , 91,	6.3	32
127	Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. <i>Journal of Immunology</i> , 2006 , 176, 5338-45	5.2	32
126	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019 , 15, e1008026	7.4	31
125	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015 , 10, e0128779	3.6	31
124	Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. <i>Journal of Virology</i> , 2013 , 87, 2294-306	6.3	31
123	N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. <i>PLoS ONE</i> , 2013 , 8, e55701	3.6	31
122	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2089-2103	15.4	31
121	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. <i>Nature Communications</i> , 2019 , 10, 47	16.9	30

120	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018 , 49, 1162-1174.e8	31.5	30
119	Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. <i>Journal of Virology</i> , 2007 , 81, 1444-50	6.3	31
118	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV,the</i> , 2019 , 6, e667-e679	7.5	31
117	Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. <i>Journal of Virology</i> , 2012 , 86, 7760-70	6.3	29
116	LY-CoV1404 potently neutralizes SARS-CoV-2 variants 2021 ,		31
115	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017 , 13, e1006074	7.4	29
114	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021 , 374, 1343-1353	32.2	30
113	HIV. The modern era of HIV-1 vaccine development. <i>Science</i> , 2015 , 349, 139-40	32.2	28
112	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. <i>Structure</i> , 2016 , 24, 1346-1357	5	28
111	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. <i>PLoS ONE</i> , 2017 , 12, e0186854	3.6	29
110	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. <i>PLoS Pathogens</i> , 2018 , 14, e1007159	7.4	27
109	Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. <i>PLoS Computational Biology</i> , 2016 , 12, e1004940	4.8	27
108	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017 , 91,	6.3	27
107	Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å crystal structure of gp120 and M48U1. <i>Structure</i> , 2013 , 21, 1018-29	5	27
106	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 18754-18763	11.2	28
105	Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1369-1377	26.8	26
104	In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. <i>Nature Protocols</i> , 2016 , 11, 193-213	18.1	26
103	Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. <i>Journal of Virology</i> , 2014 , 88, 14002-16	6.3	26

102	Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. <i>Journal of Virology</i> , 2005 , 79, 4580-8	6.3	26
101	Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 807-16	1.5	26
100	Herpes simplex virus vaccines--why don't antibodies protect?. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 379-80	26.8	26
99	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019 , 14, e0215163	3.6	25
98	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 8614-8619	11.2	25
97	BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. <i>Journal of Immunology</i> , 2012 , 188, 6018-26	5.2	25
96	Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. <i>Immunological Reviews</i> , 2017 , 275, 108-128	11	26
95	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016 , 196, 3729-43	5.2	25
94	Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. <i>Journal of Immunology</i> , 2005 , 174, 4753-60	5.2	24
93	Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1021-34	1.5	24
92	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019 , 10, 2898	16.9	23
91	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021 , 54, 1636-1651	31.5	23
90	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2021 , eabj7125	16.9	24
89	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates 2021 ,		23
88	Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. <i>Journal of Virology</i> , 2004 , 78, 5520-2	6.3	22
87	Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	9.9	21
86	Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization. <i>Journal of Immunology</i> , 2015 , 194, 5903-14	5.2	21
85	A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 213-21	1.5	21

84	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. <i>Cell</i> , 2021 ,	54.6	21
83	HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. <i>PLoS Pathogens</i> , 2014 , 10, e1004337	7.4	20
82	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. <i>Nature Communications</i> , 2020 , 11, 70	16.9	20
81	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. <i>MBio</i> , 2015 , 6,	7.6	19
80	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , 2016 , 90, 10574-10586	6.3	19
79	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018 , 14, e1007395	7.4	19
78	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020 , 31, 107488	10.3	20
77	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021 , 371,	32.2	19
76	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017 , 12, e0185959	3.6	19
75	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1007431	7.4	18
74	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020 , 6, eaba5068	13.9	18
73	Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1. <i>Cell Host and Microbe</i> , 2009 , 6, 292-4	22.9	18
72	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019 , 10, 721	16.9	17
71	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019 , 11,	16.9	16
70	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. <i>Vaccine</i> , 2015 , 33, 7344-7351	4	16
69	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. <i>Journal of Biological Chemistry</i> , 2017 , 292, 10197-10219	5.1	16
68	Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1995 , 11, 1187-95	1.5	16
67	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 2116-2127	4.3	14

66	A Monoclonal Antibody for Malaria Prevention. <i>New England Journal of Medicine</i> , 2021 , 385, 803-814	57.3	17
65	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj5413	16.9	14
64	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. 2021 ,		14
63	Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines		14
62	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020 , 222, 628-636	6.9	14
61	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018 , 13, e0193773	3.6	14
60	An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. <i>Journal of Immunology</i> , 2016 , 197, 3982-3998	5.2	12
59	Glycoengineering HIV-1 Env creates Supercharged and Hybrid Glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018 , 14, e1007024	7.4	12
58	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021 , 9,	5.1	12
57	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	16.9	13
56	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. <i>Scientific Reports</i> , 2019 , 9, 14696	4.7	11
55	Delayed vaginal SHIV infection in VRC01 and anti- $\alpha\beta$ treated rhesus macaques. <i>PLoS Pathogens</i> , 2019 , 15, e1007776	7.4	11
54	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.1	10
53	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020 , 11, 842	8.2	10
52	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020 , 16, e1007626	4.8	10
51	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021 ,	49.4	11
50	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019 , 37, 6208-6220	6.220	9
49	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020 , 12,	16.9	9

48	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020 , 11, 948	16.9	9
47	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.. <i>Science</i> , 2022 , 376, eabn8897	32.2	9
46	High throughput HIV-1 microneutralization assay. <i>Protocol Exchange</i> ,		9
45	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.. <i>Cell Reports</i> , 2022 , 39, 110812	10.3	9
44	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020 , 27, 531-543.e6	22.9	8
43	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019 , 4, 294-323	4.4	8
42	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		8
41	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019 , 9, e030283	2.9	9
40	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021 , 64, 103203	8.6	7
39	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.. <i>Cell</i> , 2022 ,	54.6	9
38	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , 2020 , 32, 107981	10.3	5
37	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants 2021 ,		6
36	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021 , 54, 769-780.e6	31.5	6
35	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. <i>BMJ Open</i> , 2020 , 10, e042247	2.9	7
34	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1530-1534	6.9	5
33	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <i>Vaccines</i> , 2020 , 8,	5.1	5
32	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529		5
31	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes 2020 ,		4

30	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1111-1120	34.3	4
29	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway 2021 ,		4
28	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1916-1924	6.9	3
27	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.. <i>Nature Medicine</i> , 2022 ,	49.4	3
26	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.. <i>Frontiers in Immunology</i> , 2021 , 12, 772864	8.2	3
25	Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates		3
24	HIV Immunology Goes Out On a Limb. <i>Immunity</i> , 2016 , 44, 1088-90	31.5	2
23	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 184-192	5.9	2
22	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization. <i>PLoS Pathogens</i> , 2021 , 17, e1009543 ^{7.4}	7.4	2
21	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies		2
20	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <i>Journal of Biological Chemistry</i> , 2021 , 297, 101127	5.1	2
19	Editorial overview: Vaccines: Vaccines for cancer and infectious diseases. <i>Current Opinion in Immunology</i> , 2015 , 35, v-vii	7.5	1
18	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. <i>Journal of Immunology</i> , 2020 , 204, 1543-1561	5.2	1
17	Blocking β Integrin delays viral rebound in SHIV-infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2021 , 13,	16.9	1
16	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , 2021 , 13, 1946918	6.4	1
15	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. 2022 ,		1
14	Broadly neutralizing antibodies target the coronavirus fusion peptide. 2022 ,		1
13	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , 2022 , 38, 110199	10.3	1

12	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. 2022 ,		1
11	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV		1
10	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
9	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. <i>PLoS Pathogens</i> , 2021 , 17, e1009738	7.4	0
8	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2.. <i>Journal of Biological Chemistry</i> , 2022 , 101819	5.1	0
7	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022 , 17, e0268767	3.6	0
6	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022 , 101477	11	0
5	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.. <i>Advanced Science</i> , 2022 , e2200063	13.2	
4	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
3	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
2	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		
1	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials 2020 , 16, e1007626		